Americafirst Capital Management buys $2,102,954 stake in Biogen Inc (BIIB)

Biogen Inc (BIIB) : Americafirst Capital Management scooped up 1,399 additional shares in Biogen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 18, 2016. The investment management firm now holds a total of 8,014 shares of Biogen Inc which is valued at $2,102,954.Biogen Inc makes up approximately 1.45% of Americafirst Capital Management’s portfolio.

Other Hedge Funds, Including , Cribstone Capital Management added BIIB to its portfolio by purchasing 90 company shares during the most recent quarter which is valued at $23,617. Biogen Inc makes up approx 0.01% of Cribstone Capital Management’s portfolio.Cim reduced its stake in BIIB by selling 14,836 shares or 58.65% in the most recent quarter. The Hedge Fund company now holds 10,459 shares of BIIB which is valued at $2,735,029. Biogen Inc makes up approx 1.33% of Cim’s portfolio.Central Bank Trust Co reduced its stake in BIIB by selling 72 shares or 0.58% in the most recent quarter. The Hedge Fund company now holds 12,342 shares of BIIB which is valued at $3,100,187. Biogen Inc makes up approx 0.87% of Central Bank Trust Co’s portfolio.Dnb Asset Management As boosted its stake in BIIB in the latest quarter, The investment management firm added 4,000 additional shares and now holds a total of 39,898 shares of Biogen Inc which is valued at $10,026,367. Biogen Inc makes up approx 0.21% of Dnb Asset Management As’s portfolio.

Biogen Inc opened for trading at $259.87 and hit $263.16 on the upside on Wednesday, eventually ending the session at $262.41, with a gain of 1.00% or 2.59 points. The heightened volatility saw the trading volume jump to 18,30,168 shares. Company has a market cap of $57,481 M.

On the company’s financial health, Biogen Inc reported $4.79 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on Apr 21, 2016. Analyst had a consensus of $4.47. The company had revenue of $2727.00 million for the quarter, compared to analysts expectations of $2745.21 million. The company’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.82 EPS.

Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.

Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.

Leave a Reply

Biogen Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Biogen Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.